Snake venom phospholipase A2 (PLA2) that induces myonecrosis, when intramuscularly injected into mice (PubMed:23509754). Does not show systemic myotoxic effect (after intravenous injection) (PubMed:23509754). Does not show cytotoxic activities in myotubes and myoblasts (PubMed:23509754). Induces marked paw edema after subplantar injections (PubMed:23509754). Also induces an increase in vascular permeability and in the levels of TNF-alpha, IL-6, and IL-1 cytokines (PubMed:23509754). causes enzymatic-dependent neuromuscular blockade in avian and mammalian neuromuscular preparations in vitro essentially by a presynaptic mechanism with no significant direct action on skeletal muscle function (PubMed:23541434, PubMed:25572337). PLA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides (PubMed:23509754). a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) Binds 1 Ca(2+) ion. Inhibited by divalent cations different from calcium ions (cadmium, magnesium, manganese, zinc), since they act as competitive antagonists of this cofactor (PubMed:23509754). Crotapotin F3 from C.durissus cascavella rattlesnake venom and antihemorrhagic factor DA2-II from D.albiventris opossum sera inhibit its enzymatic activity (PubMed:23509754). Optimum pH is 8.0. Optimum temperature is 25-37 degrees Celsius. Expressed by the venom gland. Belongs to the phospholipase A2 family. Group II subfamily. D49 sub-subfamily.